Key facts
- Akeso is expanding manufacturing of its lung cancer drug, ivonescimab.
- The drug showed positive clinical results in trials.
- Ivonescimab reduced the risk of death in a phase three trial.
- Analysts suggest the drug could become a backbone therapy in the non-small cell lung cancer market.
- Target prices for the drug have been revised upwards by analysts.
Akeso's experimental lung cancer drug, ivonescimab, has shown promising results in clinical trials, including a reduced risk of death. The company is investing to expand manufacturing, anticipating demand in China and the US, and analysts believe it could become a significant therapy in the substantial global non-small cell lung cancer market.